

In the Claims

Applicants have submitted a new complete claim set indicating marked-up claims with insertions and deletions indicated by underlining and strikeouts, respectively.

Please amend pending claims 1 and 42 as noted below.

Please cancel claim 76 as noted below.

Please amend the claims as follows:

1. (Currently Amended) A method for inhibiting cytoskeletal rearrangement in a lymphocyte, macrophage, or platelet, comprising:

contacting the lymphocyte, macrophage, or platelet with an amount of a Fyb/SLAP complex inhibitor that binds ~~Fyb/SLAP or Ena/VASP proteins~~ protein sufficient to inhibit the formation of a complex of an Ena/VASP protein and a Fyb/SLAP protein.

2. (Previously Presented) The method of claim 1, wherein the Fyb/SLAP complex inhibitor binds to the EVH1 domain of the Ena/VASP protein and inhibits binding of the Ena/VASP protein to a Fyb/SLAP protein.

3. (Cancelled)

4. (Original) The method of claim 2, wherein the Fyb/SLAP complex inhibitor comprises the peptide FPPPP (SEQ ID NO:15) or a peptide mimetic having an equivalent binding specificity.

5. (Cancelled)

6. (Withdrawn) The method of claim 1, wherein the Fyb/SLAP complex inhibitor binds a Fyb/SLAP protein and inhibits binding of an Ena/VASP protein to the Fyb/SLAP protein.

7-8. (Cancelled)

9. (Withdrawn) The method of claim 1, wherein the Fyb/SLAP complex inhibitor is an antisense nucleic acid molecule which inhibits the expression of a Fyb/SLAP protein or an Ena/VASP protein.

10-25. (Cancelled)

26. (Original) A method for inhibiting a T cell response to T cell receptor stimulation, comprising:

contacting a T cell with an amount of a Fyb/SLAP complex inhibitor sufficient to inhibit formation of a complex of a Fyb/SLAP protein and an Ena/VASP protein in the T cell.

27-29 (Cancelled)

30. (Original) The method of claim 26, wherein the Fyb/SLAP complex inhibitor binds to the EVH1 domain of the Ena/VASP protein and inhibits binding of the Ena/VASP protein to a Fyb/SLAP protein.

31-33. (Cancelled)

34. (Withdrawn) The method of claim 26, wherein the Fyb/SLAP complex inhibitor binds a Fyb/SLAP protein and inhibits binding of an Ena/VASP protein to the Fyb/SLAP protein.

35-38. (Cancelled)

39. (Original) A method for increasing platelet aggregation, comprising:

contacting a platelet with Fyb/SLAP complex inhibitor to inhibit formation of a complex of a Fyb/SLAP protein and an Ena/VASP protein in the platelet.

40-41. (Cancelled)

42. (Currently Amended) The method of claim 39, wherein the Fyb/SLAP complex inhibitor binds to the EVH1 domain of the ~~the~~ Ena/VASP protein and inhibits binding of the Ena/VASP protein to a Fyb/SLAP protein.

43-45. (Cancelled)

46. (Withdrawn) The method of claim 39, wherein the Fyb/SLAP complex inhibitor binds a Fyb/SLAP protein and inhibits binding of an Ena/VASP protein to the Fyb/SLAP protein.

47-72. (Cancelled)

73. (Previously Presented) The method of claim 2, wherein the Ena/VASP family protein is selected from the group consisting of Ena, Mena, VASP and Evl.

74. (Previously Presented) The method of claim 4, wherein the Fyb/SLAP complex inhibitor is selected from the group consisting of ActA repeats, EVH1 binding peptides, ScarWA, and dominant negative Fyb/SLAP fragments.

75-77. (Cancelled)

78. (Previously Presented) The method of claim 30, wherein the Ena/VASP family protein is selected from the group consisting of Ena, Mena, VASP and Evl.

79. (Previously Presented) The method of claim 30, wherein the Fyb/SLAP complex inhibitor comprises the peptide FPPPP (SEQ ID NO:15) or a peptide mimetic having an equivalent binding specificity.

80. (Previously Presented) The method of claim 79, wherein the Fyb/SLAP complex inhibitor is selected from the group consisting of ActA repeats, EVH1 binding peptides, ScarWA, and dominant negative Fyb/SLAP fragments.

81. (Previously Presented) The method of claim 42, wherein the Ena/VASP family protein is selected from the group consisting of Ena, Mena, VASP and Evl.

82. (Previously Presented) The method of claim 42, wherein the Fyb/SLAP complex inhibitor comprises the peptide FPPPP (SEQ ID NO:15) or a peptide mimetic having an equivalent binding specificity.

83. (Previously Presented) The method of claim 82, wherein the Fyb/SLAP complex inhibitor is selected from the group consisting of ActA repeats, EVH1 binding peptides, ScarWA, and dominant negative Fyb/SLAP fragments.

84. (Withdrawn) The method of claim 39, wherein the Fyb/SLAP complex inhibitor binds a Fyb/SLAP protein and inhibits binding of an Ena/VASP protein to the Fyb/SLAP protein.